Until there is, the answer is no
the SURMOUNT and SURPASS programs showed ~22% weight loss
8.16% placebo at the end of the study) and there wasn't much of a difference between the groups - this brings into question the mechanism behind CV risk reduction The empagliflozin group had small decreases in weight, waist circumference, uric acid level, and blood pressure but small increases in LDL and HDL Rates of hypoglycemia were comparable among study groups About empagliflozin Empagliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor which works by blocking the reabsorption of glucose by the kidney, allowing it to pass out of the body through the urine (usually the kidney reabsorbs all of the filtered glucose)
Indeed, many doctors require people to try diet and exercise alone before trying GLP-1s
When you stop taking either drug, your blood sugar may rise and you may gain weight
Obesity While at the most basic level, obesity is caused by a person taking in more energy than they expend over a prolonged period, it is worth noting that humans have a complex neural mechanism regulating food intake, which is generally very effective at maintaining a balance between energy intake and expenditure
